Kenya's Ministry of Health has unveiled a sweeping regulatory overhaul designed to curb counterfeit and substandard medicines, with pharmaceutical imports required to meet strict digital identification rules beginning in January.

The framework was announced at the Kenya Health Summit in Nairobi. Under it, imported medical products must carry unique serialized digital identifiers, and a centralized track-and-trace system will allow regulators, pharmacists and consumers to verify products and monitor their movement through the pharmaceutical supply chain.

Imported medicines will need to carry unique digital fingerprints that can be validated through a blockchain-backed tracking system, producing a digital record that spans manufacture, distribution and the point of dispensing.

The initiative targets a long-standing counterfeit medicine problem that porous borders within the East African Community have helped facilitate. Investigations by the Pharmacy and Poisons Board have uncovered falsified antiretroviral medicines, rapid HIV testing kits and lifestyle drugs circulating through informal pharmacies and other unregulated outlets in major cities including Nairobi and Mombasa.

Digital tracking targets counterfeit supply chains

Under the proposed system, every pharmaceutical product would be assigned a serialized digital identity that can be checked at different stages of the supply chain. The technology is expected to generate a tamper-resistant record tracing a medicine from its manufacturing location to its final point of distribution.

The framework draws in part on serialization and pharmaceutical tracking systems already used in developed markets. The European Union's Falsified Medicines Directive, adopted in 2011, has required a unique identifier and tamper-evident packaging on most prescription medicines since February 2019, while the United States phased in serialization and product-tracing rules under the Drug Supply Chain Security Act of 2013. Those regimes run on centralized verification databases rather than distributed ledgers, making the blockchain-backed architecture Kenya has chosen a departure from the approach used in those markets. The government intends to use cryptographic verification to distinguish legitimate products from those that enter the country outside approved channels.

Medicines that fail the required verification process could be flagged for enforcement action. The framework would enable authorities, including the Kenya Revenue Authority and border control agencies, to identify potentially counterfeit or unauthorized products during importation and distribution.

Pharmacists and consumers are also expected to gain improved visibility. Rather than relying solely on packaging or conventional documentation, users would be able to confirm a product's digital identity through the centralized platform.

Counterfeit medicines threaten health and industry

Kenyan authorities regard the counterfeit medicine trade as both a public health and an economic concern. Substandard medicines can expose patients to ineffective treatment, while falsified products may contain incorrect ingredients or inadequate quantities of active pharmaceutical substances.

The problem also contributes to antimicrobial resistance, particularly when patients receive antibiotics that do not contain sufficient therapeutic doses. Health Cabinet Secretary Deborah Barasa has linked stronger medicine verification to efforts to reduce the growing burden of antimicrobial resistance.

The World Health Organization has estimated that about one in ten medical products in low- and middle-income countries is substandard or falsified, underscoring the scale of the challenge facing regulators and healthcare systems. African regulators have deployed technology-based authentication before: Nigeria's drug agency, NAFDAC, has for more than a decade required scratch-off PINs on certain high-risk medicines such as antimalarials, which consumers verify by SMS.

The government expects the system to strengthen medicine safety while helping authorities identify counterfeit products before they reach pharmacies, clinics and patients.

The counterfeit trade also creates difficulties for legitimate pharmaceutical manufacturers. Kenya's pharmaceutical industry contributes an estimated KSh 40 billion annually to the national economy, while multinational manufacturers have identified counterfeiting and intellectual property violations as obstacles to expanding local production.

Those concerns are particularly relevant as Kenya seeks to develop pharmaceutical manufacturing centers in areas such as Konza and Tatu City. Stronger supply-chain controls could improve confidence among manufacturers considering investment in local production and distribution.

Importers prepare for January deadline

With the January implementation deadline approaching, pharmaceutical importers and domestic distributors are working to connect their inventory management systems with the Ministry of Health's digital gateway. The import focus covers most of the market: the majority of medicines used in Kenya are imported, with India and China among the leading suppliers, so much of the compliance work falls on importers and their overseas manufacturing partners.

The transition is expected to require changes in inventory management, product identification and supply-chain reporting. Companies will need to ensure that imported medicines receive the required digital identifiers and remain traceable throughout distribution.

The digital track-and-trace framework could establish a new model for pharmaceutical regulation in Kenya by combining product serialization, blockchain-backed records and real-time verification across the medicine supply chain.

If implemented effectively, the system could provide regulators with greater visibility into pharmaceutical imports while giving healthcare providers and consumers an additional mechanism for confirming product authenticity. Kenya's approach could also offer a potential regulatory template for other African markets facing similar counterfeit medicine and supply-chain challenges.